Journal articles
Coleman RL; Fleming GF; Brady MF; Swisher E; Steffensen KD; Friedlander M; Okamoto A; Moore K; Ben-Baruch N; Werner TL; Oaknin A; Nam J-H; Leath CA; Nicum S; Cella D; Sullivan DM; Ansell PJ; Dinh M; Aghajanian C; Bookman MA, 2019, 'VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)', Annals of Oncology, 30, pp. v895 - v896, http://dx.doi.org/10.1093/annonc/mdz394.054
Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer', New England Journal of Medicine, 379, pp. 2495 - 2505, http://dx.doi.org/10.1056/NEJMoa1810858
Beesley VL; Smith DD; Nagle CM; Friedlander M; Grant P; DeFazio A; Webb PM, 2018, 'Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer', Supportive Care in Cancer, 26, pp. 4133 - 4142, http://dx.doi.org/10.1007/s00520-018-4284-0
Joo JE; Dowty JG; Milne RL; Wong EM; Dugué PA; English D; Hopper JL; Goldgar DE; Giles GG; Southey MC; Sexton A; Christian A; Trainer A; Spigelman A; Fellows A; Shelling A; De Fazio A; Blackburn A; Crook A; Meiser B; Patterson B; Clarke C; Saunders C; Hunt C; Scott C; Amor D; Marsh D; Edkins E; Salisbury E; Haan E; Neidermayr E; Macrae F; Farshid G; Lindeman G; Chenevix-Trench G; Mann G; Gill G; Thorne H; Campbell I; Hickie I; Winship I; Goldblatt J; Flanagan J; Kollias J; Visvader J; Stone J; Taylor J; Burke J; Saunus J; Forbes J; Beesley J; Kirk J; French J; Tucker K; Wu K; Phillips K; Lipton L; Andrews L; Lobb E; Walker L; Kentwell M; Spurdle A; Cummings M; Gleeson M; Harris M; Jenkins M; Young MA; Delatycki M; Wallis M; Burgess M; Price M; Brown M; Bogwitz M; Field M; Friedlander M; Gattas M; Saleh M; Hayward N; Pachter N; Cohen P; Duijf P; James P; Simpson P; Fong P; Butow P; Williams R; Kefford R; Scott R; Balleine R; Dawson SJ; Lok S; O'Connell S; Greening S; Nightingale S; Edwards S; Fox S; McLachlan SA; Lakhani S; Thomas S; Antill Y, 2018, 'Heritable DNA methylation marks associated with susceptibility to breast cancer /631/67/69 /631/337/176/1988 /692/699/67/1347 /692/308/2056 /45 /45/61 article', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-03058-6
Kondrashova O; Topp M; Nesic K; Lieschke E; Ho GY; Harrell MI; Zapparoli GV; Hadley A; Holian R; Boehm E; Heong V; Sanij E; Pearson RB; Krais JJ; Johnson N; McNally O; Ananda S; Alsop K; Hutt KJ; Kaufmann SH; Lin KK; Harding TC; Traficante N; Chenevix-Trench G; Green A; Webb P; Gertig D; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J, 2018, 'Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-05564-z
Friedlander M; Shannon C; Goh J; Scott C; Mileshkin L, 2018, 'Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib', Asia-Pacific Journal of Clinical Oncology, 14, pp. 459 - 464, http://dx.doi.org/10.1111/ajco.13104
Hopper JL; Dite GS; MacInnis RJ; Liao Y; Zeinomar N; Knight JA; Southey MC; Milne RL; Chung WK; Giles GG; Genkinger JM; McLachlan SA; Friedlander ML; Antoniou AC; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; Daly MB; John EM; Phillips KA; Terry MB, 2018, 'Age-specific breast cancer risk by body mass index and familial risk: Prospective family study cohort (ProF-SC)', Breast Cancer Research, 20, http://dx.doi.org/10.1186/s13058-018-1056-1
Friedlander M; Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; González-Martín A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; Disilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. ix174 - ix175, http://dx.doi.org/10.1093/annonc/mdy483.002
Friedlander M; Matulonis U; Gourley C; du Bois A; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Shirinkin V; Selle F; Fielding A; Lowe ES; McMurtry EL; Spencer S; Rowe P; Mann H; Parry D; Ledermann J, 2018, 'Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy', British Journal of Cancer, 119, pp. 1075 - 1085, http://dx.doi.org/10.1038/s41416-018-0271-y
Berek JS; Kehoe ST; Kumar L; Friedlander M, 2018, 'Cancer of the ovary, fallopian tube, and peritoneum', International Journal of Gynecology and Obstetrics, 143, pp. 59 - 78, http://dx.doi.org/10.1002/ijgo.12614
Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA, 2018, 'Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study', Gynecologic Oncology, 151, pp. 18 - 23, http://dx.doi.org/10.1016/j.ygyno.2018.07.021
Terry MB; Liao Y; Kast K; Antoniou AC; McDonald JA; Mooij TM; Engel C; Nogues C; Buecher B; Mari V; Moretta-Serra J; Gladieff L; Luporsi E; Barrowdale D; Frost D; Henderson A; Brewer C; Evans DG; Eccles D; Cook J; Ong KR; Izatt L; Ahmed M; Morrison PJ; Dommering CJ; Oosterwijk JC; Ausems MGEM; Kriege M; Buys SS; Andrulis IL; John EM; Daly M; Friedlander M; McLachlan SA; Osorio A; Caldes T; Jakubowska A; Simard J; Singer CF; Tan Y; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Arver B; Olsson H; Schmutzler RK; Hopper JL; van Leeuwen FE; Goldgar D; Milne RL; Easton DF; Rookus MA; Andrieu N, 2018, 'The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations', JNCI Cancer Spectrum, 2, http://dx.doi.org/10.1093/JNCICS/PKY078
Wilson MK; Mercieca-Bebber R; Friedlander M, 2018, 'A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer', Journal of Gynecologic Oncology, 29, http://dx.doi.org/10.3802/jgo.2018.29.e81
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML, 2018, 'Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials', Gynecologic Oncology, 150, pp. 527 - 533, http://dx.doi.org/10.1016/j.ygyno.2018.07.013
Friedlander M; Gebski V; Gibbs E; Davies L; Bloomfield R; Hilpert F; Wenzel LB; Eek D; Rodrigues M; Clamp A; Penson RT; Provencher D; Korach J; Huzarski T; Vidal L; Salutari V; Scott C; Nicoletto MO; Tamura K; Espinoza D; Joly F; Pujade-Lauraine E, 2018, 'Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial', The Lancet Oncology, 19, pp. 1126 - 1134, http://dx.doi.org/10.1016/S1470-2045(18)30343-7
Loo CKC; Danieletto S; Friedlander M; Pearen MA; Ramm GA, 2018, 'Peritoneal hepatoid carcinoma with chemotherapy response and possible stem cell involvement', Human Pathology: Case Reports, 12, pp. 71 - 76, http://dx.doi.org/10.1016/j.ehpc.2018.02.008
Grimison PS; Lawrence NJ; Stockler MR; Martin AJ; Yip S; Wong N; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn DI; McDermott R; Walker R; Winstanley M; Hanning FJ; Weickhardt AJ; Stevanovic AG; Davis ID; Toner GC, 2018, 'P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).', Journal of Clinical Oncology, 36, pp. TPS4596 - TPS4596, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.tps4596
Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK, 2018, 'Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers a systematic review and meta-analysis', JAMA Oncology, 4, pp. 522 - 528, http://dx.doi.org/10.1001/jamaoncol.2017.5236
Oskay-Özcelik G; Alavi S; Richter R; Keller M; Chekerov R; Cecere SC; Cormio G; Joly F; Kurtz JE; du Bois A; Maciejewski M; Jedryka M; Vergote I; Van Nieuwenhuysen E; Casado A; Mendiola C; Achimas-Cadariu P; Vlad C; Reimer D; Zeimet AG; Friedlander M; Sehouli J, 2018, 'Expression III: Patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries', Annals of Oncology, 29, pp. 910 - 916, http://dx.doi.org/10.1093/annonc/mdy037
Schrijver LH; Olsson H; Phillips KA; Terry MB; Goldgar DE; Kast K; Engel C; Mooij TM; Adlard J; Barrowdale D; Davidson R; Eeles R; Ellis S; Evans DG; Frost D; Izatt L; Porteous ME; Side LE; Walker L; Berthet P; Bonadona V; Leroux D; Mouret-Fourme E; Venat-Bouvet L; Buys SS; Southey MC; John EM; Chung WK; Daly MB; Bane A; van Asperen CJ; Garcia EBG; Mourits MJE; Roos-Blom MJ; Friedlander ML; McLachlan SA; Singer CF; Foretova L; Gerdes AM; Caldes T; Olah E; Jakubowska A; Noguès C; Andrieu N; Easton DF; van Leeuwen FE; Hopper JL; Milne RL; Antoniou AC; Rookus MA; Laborde L; Pontois P; Stoppa-Lyonnet D; Gauthier-Villars M; Buecher B; Caron O; Fricker JP; Lasset C; Faivre L; Luporsi E; Frénay M; Gladieff L; Gesta P; Sobol H; Eisinger F; Moretta J; Longy M; Dugast C; Colas C; Soubrier F; Coupier I; Pujol P; Lortholary A; Vennin P; Adenis C; Nguyen TD; Delnatte C; Rossi A; Tinat J; Tennevet I; Limacher JM; Maugard C; Bignon YJ; Demange L; Dreyfus H; Cohen-Haguenauer O; Gilbert B; Zattara-Cannoni H, 2018, 'Oral contraceptive use and breast cancer risk: Retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study', JNCI Cancer Spectrum, 2, http://dx.doi.org/10.1093/jncics/pky023
Sousa M; Peate M; Lewis C; Jarvis S; Willis A; Hickey M; Friedlander M, 2018, 'Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy', European Journal of Cancer Care, 27, http://dx.doi.org/10.1111/ecc.12820
Block MS; Vierkant RA; Rambau PF; Winham SJ; Wagner P; Traficante N; Toloczko A; Tiezzi DG; Taran FA; Sinn P; Sieh W; Sharma R; Rothstein JH; Ramón y Cajal T; Paz-Ares L; Oszurek O; Orsulic S; Ness RB; Nelson G; Modugno F; Menkiszak J; McGuire V; McCauley BM; Mack M; Lubinski J; Longacre TA; Li Z; Lester J; Kennedy CJ; Kalli KR; Jung AY; Johnatty SE; Jimenez-Linan M; Jensen A; Intermaggio MP; Hung J; Herpel E; Hernandez BY; Hartkopf AD; Harnett PR; Ghatage P; García-Bueno JM; Gao B; Fereday S; Eilber U; Edwards RP; de Sousa CB; de Andrade JM; Chudecka-Glaz A; Chenevix-Trench G; Cazorla A; Brucker SY; Bowtell DD; Green A; Webb P; de Fazio A; Gertig D; Moore S; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R, 2018, 'MyD88 and TLR4 Expression in Epithelial Ovarian Cancer', Mayo Clinic Proceedings, 93, pp. 307 - 320, http://dx.doi.org/10.1016/j.mayocp.2017.10.023
Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A, 2018, 'Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy', Annals of Oncology, 29, pp. 737 - 743, http://dx.doi.org/10.1093/annonc/mdx796
Wilson MK; Friedlander ML; Joly F; Oza AM, 2018, 'A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve', Oncologist, 23, pp. 203 - 213, http://dx.doi.org/10.1634/theoncologist.2017-0297
Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Gares V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart C; Sharma R; Allan PE; Rambau PF; Traficante N; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Kobel M; Harnett P; Nelson BH; Bowtell DDL; DeFazio A, 2018, 'Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer', Clinical Cancer Research, 24, pp. 569 - 580, http://dx.doi.org/10.1158/1078-0432.CCR-17-1621
Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M, 2018, 'Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients', Gynecologic Oncology, 148, pp. 79 - 85, http://dx.doi.org/10.1016/j.ygyno.2017.10.036
King MT; Stockler MR; O’Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML, 2018, 'Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer', Quality of Life Research, 27, pp. 59 - 74, http://dx.doi.org/10.1007/s11136-017-1729-8
Kirk J; Barlow-Stewart KK; Poplawski NK; Gleeson M; Tucker K; Friedlander M, 2018, 'Medicare-funded cancer genetic tests: A note of caution clinicians need appropriate education and support in keeping pace with the genomics revolution', Medical Journal of Australia, 209, pp. 193 - 196.e1, http://dx.doi.org/10.5694/mja17.01124
Sjoquist KM; Lord SJ; Friedlander ML; John Simes R; Marschner IC; Lee CK, 2018, 'Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis', Therapeutic Advances in Medical Oncology, 10, http://dx.doi.org/10.1177/1758835918788500
Mercieca-Bebber R; King MT; Calvert MJ; Stockler MR; Friedlander M, 2018, 'The importance of patient-reported outcomes in clinical trials and strategies for future optimization', PATIENT-RELATED OUTCOME MEASURES, 9, pp. 353 - 367, http://dx.doi.org/10.2147/PROM.S156279
Zalcberg JR; Friedlander M, 2018, 'The value of participating in clinical trials: The whole is greater than the sum of its parts', Medical Journal of Australia, 209, http://dx.doi.org/10.5694/mja17.01266
Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M, 2018, 'Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)', Gynecologic Oncology, 148, pp. 36 - 41, http://dx.doi.org/10.1016/j.ygyno.2017.10.019
Han HS; Diéras V; Robson M; Palácová M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Garber JE; Shparyk Y; Chmielowska E; Jakobsen EH; Kaklamani V; Gradishar W; Ratajczak CK; Nickner C; Qin Q; Qian J; Shepherd SP; Isakoff SJ; Puhalla S, 2018, 'Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: Randomized phase II study', Annals of Oncology, 29, pp. 154 - 161, http://dx.doi.org/10.1093/annonc/mdx505
Deva S; Lee J-S; Lin C-C; Yen C-J; Millward M; Chao Y; Keam B; Jameson M; Hou M-M; Kang Y-K; Markman B; Lu C-H; Rau K-M; Lee K-H; Horvath L; Friedlander M; Hill A; Wu J; Hou J; Desai J, 2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', Annals of Oncology, 29, pp. x24 - x25, http://dx.doi.org/10.1093/annonc/mdy487.042
Sandhu S; Hill A; Gan H; Friedlander M; Voskoboynik M; Barlow P; Townsend A; Song J; Zhang Y; Liang L; Desai J, 2018, 'Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study', Annals of Oncology, 29, pp. x28 - x28, http://dx.doi.org/10.1093/annonc/mdy487.007
Kovalenko S; Crooks R; Provan P; de Fazio A; Taylor P; Kennedy B; Friedlander M; Caramins M, 2018, 'Tumour profiling for treatment of patients with ovarian cancers', Pathology, 50, pp. S77 - S77, http://dx.doi.org/10.1016/j.pathol.2017.12.200
Park SB; Kwok JB; Asher R; Lee CK; Beale P; Selle F; Friedlander M, 2017, 'Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial', Annals of Oncology, 28, pp. 2733 - 2740, http://dx.doi.org/10.1093/annonc/mdx491
Bookman MA; Okamoto A; Stuart G; Yanaihara N; Aoki D; Bacon M; Fujiwara K; González-Martín A; Harter P; Kim JW; Ledermann J; Pujade-Lauraine E; Quinn M; Ochiai K; Zeimet A; Marth C; du Bois A; Hilpert F; Pfisterer J; Reuss A; Friedlander M; Wilson MK; Kridelka F; Vergote I; Berek J; Dorigo O; Karam A; Bekkers RLM; Westermann A; Gatsonis C; Ng C; Herráez AC; Ottevanger N; Poveda A; Redondo A; Coleman R; Lu K; Gallardo-Rincón D; Gomez-Garcia E; Joly F; Leary A; Ray-Coquard I; Burger R; Moore KN; Fujiwara H; Hasegawa K; Gleeson N; Levy T; Rosengarten O; Katsumata N; Silverberg SG; Sugiyama T; Chang SJ; Kim BG; Nam BH; Colombo N; Ferrero A; Lorusso D; Scambia G; Edmondson R; McNeish I; Kohn E; Hirte H; McGee J; Provencher D; Sehouli J; Wimberger P; Maenpaa J; Mirza MR; Oza A; Welch S; Gaffney D; Small W; Glasspool R; Gourley C; Millan D; Zang R; Zhu J, 2017, 'Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference', Annals of Oncology, 28, pp. viii30 - viii35, http://dx.doi.org/10.1093/annonc/mdx449
Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA; Buck M; Dean A; Friedlander ML; Harnett P; Kichenadasse G; Denys H; Dirix L; Vergote I; Elit L; Ghatage P; Plante M; Provencher D; Welch S; Gladieff L; Joly F; Lortholary A; Lotz J; Medioni J; Tredan O; You B; El-Balat A; Hänle C; Krabisch P; Neunhöffer T; Pölcher M; Wimberger P; Amit A; Kovel S; Leviov M; Safra T; Shapira-Frommer R; Stemmer S; Bologna A; Pignata S; Sabbatini RF; Tamberi S; Zamagni C; O'Donnell A; Herraez AC; Guerra EM; Palacio I; Romero I; Sanchez A; Banerjee SN; Drew Y; Gabra HG; Jackson D; Parkinson C; Powell M; Birrer MJ; Buss MK; Chambers SK; Chen LM; Ma L; Morgan MA; Morris RT; Mutch DG; Slomovitz BM; Vanderkwaak T; Vulfovich M, 2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet, 390, pp. 1949 - 1961, http://dx.doi.org/10.1016/S0140-6736(17)32440-6
Coleman RL; Oza AM; Lorusso D, 2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 390, pg 1949, 2017)', LANCET, 390, pp. 1948 - 1948, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413823200030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lee YC; Bressel M; Grant P; Russell P; Smith C; Picken S; Camm S; Kiely BE; Milne RL; McLachlan SA; Hickey M; Friedlander ML; Hopper JL; Phillips KA, 2017, 'Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer', Familial Cancer, 16, pp. 461 - 469, http://dx.doi.org/10.1007/s10689-017-9977-x
Lee YC; Milne RL; Lheureux S; Friedlander M; McLachlan SA; Martin KL; Bernardini MQ; Smith C; Picken S; Nesci S; Hopper JL; Phillips KA, 2017, 'Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers', European Journal of Cancer, 84, pp. 114 - 120, http://dx.doi.org/10.1016/j.ejca.2017.07.004
Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard IL; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P; Byrski T; Colombo N; Scambia G; Nicoletto M; Nussey F; Clamp A; Poveda Velasco A; Rodrigues M; Lotz JP; Provencher D; Prat Aparicio A; Vidal Boixader L; Scott C; Tamura K; Yunokawa M; Lisyanskaya A; Medioni J; Pécuchet N; Dubot C; de la Motte Rouge T; Kaminsky MC; Weber B; Lortholary A; Parkinson C; Williams S; Cosin J; Hoffman J; Plante M; Covens A; Sonke G; Joly F; Floquet A; Hirte H; Amit A; Park-Simon TW; Matsumoto K; Tjulandin S; Kim JH; Gladieff L; Sabbatini R; O'Malley D; Timmins P; Kredentser D; Laínez Milagro N; Barretina Ginesta MP; Tibau Martorell A; Gómez de Liaño Lista A; Ojeda González B; Mileshkin L; Mandai M; Boere I; Ottevanger P; Nam JH; Filho E; Hamizi S; Cognetti F; Warshal D; Dickson-Michelson E; Kamelle S; McKenzie N; Rodriguez G; Armstrong D; Chalas E; Celano P; Behbakht K; Davidson S; Welch S; Helpman L; Fishman A; Bruchim I, 2017, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial', The Lancet Oncology, 18, pp. 1274 - 1284, http://dx.doi.org/10.1016/S1470-2045(17)30469-2
Roncolato FT; Joly F; O’Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M, 2017, 'Reducing uncertainty: Predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer—The GCIG symptombenefit study', Oncologist, 22, pp. 1117 - 1124, http://dx.doi.org/10.1634/theoncologist.2017-0047
Gligorov J; Ataseven B; Verrill M; de Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X; Koroveshi D; Bouzid K; Casalnuovo M; Cascallar D; Korbenfeld EP; Bastick P; Beith J; Colosimo M; Friedlander M; Ganju V; Green M; Patterson K; Redfern A; Richardson G; Ceric T; Gordana K; Beato CA; Ferrari M; Hegg R; Helena V; Ismael GF; Lessa AE; Mano M; Morelle A; Nogueira JA; Timcheva K; Tomova A; Tsakova M; Zlatareva-Petrova A; Asselah J; Assi H; Brezden-Masley C; Chia S; Freedman O; Harb M; Joy AA; Kulkarni S; Prady C; Gaete AAA; Matamala L; Torres R; Yanez E; Franco S; Urrego M; Gugić D; Vrbanec D; Melichar B; Prausová J; Vyzula R; Pilarte RG; León MI; Muñoz R; Ramos G; Azeem HA; Aziz AA; El Zawahry H; Osegueda FR; Alexandre J; Artignan X; Barletta H; Beguier E; Berdah JF; Marty CB; Bollet M; Bourgeois H; Bressac C; Burki F; Campone M; Coeffic D; Cojocarasu OZ; Dagada C; Dalenc F; Del Piano F; Desauw C; Desmoulins I; Dohollou N; Egreteau J; Ferrero JM; Foa C; Garidi R; Gasnault L; Guardiola E; Hamizi S; Jarcau R; Jacquin JP; Jaubert D; Jolimoy G; Mineur HL; Largillier R; Leduc B, 2017, 'Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients', European Journal of Cancer, 82, pp. 237 - 246, http://dx.doi.org/10.1016/j.ejca.2017.05.010
Kondrashova O; Nguyen M; Shield-Artin K; Tinker AV; Teng NNH; Harrell MI; Kuiper MJ; Ho GY; Barker H; Jasin M; Prakash R; Kass EM; Sullivan MR; Brunette GJ; Bernstein KA; Coleman RL; Floquet A; Friedlander M; Kichenadasse G; O’Malley DM; Oza A; Sun J; Robillard L; Maloney L; Bowtell D; Giordano H; Wakefield MJ; Kaufmann SH; Simmons AD; Harding TC; Raponi M; McNeish IA; Swisher EM; Lin KK; Scott CL, 2017, 'Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma', Cancer Discovery, 7, pp. 984 - 998, http://dx.doi.org/10.1158/2159-8290.CD-17-0419
Mercieca-Bebber R; Friedlander M; Kok PS; Calvert M; Kyte D; Stockler M; King MT, 2017, 'Erratum to: The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols (Quality of Life Research, (2016), 25, 10, (2457-2465), 10.1007/s11136-016-1339-x)', Quality of Life Research, 26, pp. 2249 - 2250, http://dx.doi.org/10.1007/s11136-017-1578-5
Roncolato FT; Gibbs E; Lee CK; Asher R; Davies LC; Gebski VJ; Friedlander M; Hilpert F; Wenzel L; Stockler MR; King M; Pujade-Lauraine E, 2017, 'Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: An AURELIA substudy', Annals of Oncology, 28, pp. 1849 - 1855, http://dx.doi.org/10.1093/annonc/mdx229
Samimi G; Caga-Anan CF; Dean M; Mechanic LE; Minasian LM; Sherman ME; Brody LC; Bernardini MQ; Lheureux S; Shaw PA; Kwon JS; Campbell IG; James PA; Takenaka M; Bowtell DD; Chenevix-Trench G; Friedlander M; Ramus SJ; Couch FJ; De Hullu JA; Harmsen MG; Domchek SM; Drapkin R; Mai PL; Feigelson HS; Gaudet MM; Hurley K; Robson ME; Lacbawan F; Slavin TP; Myers ER; Rezende LF; Swisher EM, 2017, 'Traceback: A proposed framework to increase identification and genetic counseling of BRCA1 and BRCA2 mutation carriers through family-based outreach', Journal of Clinical Oncology, 35, pp. 2329 - 2337, http://dx.doi.org/10.1200/JCO.2016.70.3439
Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H, 2017, 'Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', JAMA, 317, pp. 2402 - 2416, http://dx.doi.org/10.1001/jama.2017.7112
Back to profile page
https://orcid.org/0000-0003-3090-795X